oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes 🔴Cardiovascular with by severity of chronic kidney disease diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants Frontiers | Effects of subcutaneous

What we know is that the active ingredient is the same, the mechanism of action is identical, and the clinical evidence for semaglutides effectiveness comes from the molecule itself rather than the delivery format

Weekly 15-minute visits that include: Weigh In Symptom assessment Your weekly injection All participants start at a dosage of 0.25mg

What it is not: a replacement for a GLP-1 medication, and not a treatment for stress, appetite, or any medical condition

Dr Tee was a fantastic doctor

At the time of this writing, liraglutide is the only GLP-1 RA with a labeled indication to reduce the risk of major adverse cardiovascular events (MACE), yet several other GLP-1 RAs have shown significant reduction in MACE, as summarized in Table 2